Levomilnacipran is an antidepressant currently approved in Canada to treat Major Depressive
Disorder (MDD). Thirty-six healthy male participants will receive escalating doses of
levomilnacipran, duloxetine, or placebo every 7 days (+/- 1 day) throughout a 20 - 28 day
period. After each dose escalation study participants will be asked to come to the clinic to
conduct the necessary tests - these will include tyramine pressor tests as well as blood
draws. The results of this study will allow the investigators to determine the dose(s) of
levomilnacipran at which reuptake inhibition of norepinephrine and serotonin (chemicals
utilized by nerve cells to transmit information to other cells) is achieved.